Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

被引:8
|
作者
Sanchez Hernandez, Alfredo [1 ]
Jose Juan, Oscar [2 ]
Vidal Martinez, Jose [3 ]
Blanco, Remei [4 ]
Macia, Sonia [5 ]
Esquerdo Galiana, Gaspar [6 ]
Aparisi Aparisi, Francisco [7 ]
Garde Noguera, Javier [8 ]
Catot, Silvia [9 ]
Losa Gaspa, Ferran [10 ]
Garcia-Pinon, Francisco [11 ]
机构
[1] Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
[2] Hosp Univ & Politecn La Fe, Med Oncol Serv, Valencia, Spain
[3] Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
[4] Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
[5] Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
[6] Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
[7] Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
[8] Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
[9] Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
[10] Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
[11] Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
关键词
Circulating endothelial cell; NSCLC; Chemotherapy; PACLITAXEL-CARBOPLATIN; PERIPHERAL-BLOOD; SURROGATE MARKER; CLINICAL-VALUE; CANCER; ANGIOGENESIS; BEVACIZUMAB; PROGENITORS; CISPLATIN; SURVIVAL;
D O I
10.1007/s12094-014-1223-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch). The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance. In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 50 条
  • [21] Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy
    Najjar, Fadi
    Al-Massarani, Ghassan
    Banat, Israa
    Alammar, Moosheer
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (04) : E374 - E381
  • [22] Pemetrexed in advanced non-small cell lung cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Zeppa, Rosario
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (02) : 311 - 317
  • [23] Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
    Felipe Cardona, Andres
    Rojas, Leonardo
    Wills, Beatriz
    Arrieta, Oscar
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Cuello, Mauricio
    Corrales, Luis
    Martin, Claudio
    Ortiz, Carlos
    Franco, Sandra
    Rosell, Rafael
    PLOS ONE, 2016, 11 (05):
  • [24] Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan
    Asami, Kazuhiro
    Kawahara, Masaaki
    Hirashima, Tomonori
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Omachi, Naoki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Hirooka, Aya
    Nakao, Keiko
    Tsuji, Taisuke
    Atagi, Shinji
    THORACIC CANCER, 2014, 5 (04) : 289 - 296
  • [25] The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma
    Yang, Chih-Jen
    Tsai, Ying-Ming
    Tsai, Ming-Ju
    Chang, Hsu-Liang
    Huang, Ming-Shyan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 199 - 205
  • [26] Molecular landscape of non-squamous, non-small cell carcinoma of the lung
    Weiss, Mia C.
    Leukam, Michael J.
    Villaflor, Victoria M.
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (04) : 423 - 434
  • [27] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Yaru Tian
    Hairong Tian
    Xiaoyang Zhai
    Hui Zhu
    Jinming Yu
    Frontiers of Medicine, 2022, 16 : 610 - 617
  • [28] Clinical efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer
    Liu, Yuhua
    Mao, Aihong
    Ma, Qin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 9049 - 9057
  • [29] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer:a retrospective analysis
    Yaru Tian
    Hairong Tian
    Xiaoyang Zhai
    Hui Zhu
    Jinming Yu
    Frontiers of Medicine, 2022, 16 (04) : 610 - 617
  • [30] Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study
    Yang, Guangjian
    Xu, Haiyan
    Yang, Lu
    Xu, Fei
    Zhang, Shuyang
    Yang, Yaning
    Wang, Yan
    LUNG CANCER, 2020, 147 : 229 - 236